Rheumatoid Arthritis

You have full text access to this OnlineOpen article

The relationship between focal erosions and generalized osteoporosis in postmenopausal women with rheumatoid arthritis

  1. Daniel H. Solomon1,†,*,
  2. Joel S. Finkelstein2,
  3. Nancy Shadick1,‡,
  4. Meryl S. LeBoff1,§,
  5. Carl S. Winalski3,¶,
  6. Margaret Stedman1,
  7. Roberta Glass1,
  8. M. Alan Brookhart1,
  9. Michael E. Weinblatt1,‖,
  10. Ellen M. Gravallese4,††

Article first published online: 28 MAY 2009

DOI: 10.1002/art.24551

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 60, Issue 6, pages 1624–1631, June 2009

Additional Information

How to Cite

Solomon, D. H., Finkelstein, J. S., Shadick, N., LeBoff, M. S., Winalski, C. S., Stedman, M., Glass, R., Brookhart, M. A., Weinblatt, M. E. and Gravallese, E. M. (2009), The relationship between focal erosions and generalized osteoporosis in postmenopausal women with rheumatoid arthritis. Arthritis & Rheumatism, 60: 1624–1631. doi: 10.1002/art.24551

Author Information

  1. 1

    Brigham and Women's Hospital, Boston, Massachusetts

  2. 2

    Massachusetts General Hospital, Boston

  3. 3

    Cleveland Clinic Foundation, Cleveland, Ohio

  4. 4

    University of Massachusetts Medical Center, Worcester

  1. †

    Dr. Solomon has received research grants from Abbott and Amgen, and has served as an unpaid member of the Data Safety and Monitoring Board and the Trial Executive Committee for Pfizer.

  2. ‡

    Dr. Shadick has received research grants from the Amgen Foundation, the Bristol-Myers Squibb Foundation, Millennium Pharmaceuticals, Biogen Idec, and Crescendo Therapeutics.

  3. §

    Dr. LeBoff owns stock or stock options in GE and Amgen.

  4. Dr. Winalski owns stock or stock options in Pfizer, has received research support from Abbott, and has served as an investigator for research at the Cleveland Clinic funded through a contract with Abbott.

  5. ‖

    Dr. Weinblatt has received consulting fees and/or research funding from Abbott, Amgen, Biogen Idec, Bristol-Myers Squibb, Genentech, Millennium Pharmaceuticals, and Riley Genomics (less than $10,000 each). He has received consulting fees from Crescendo Therapeutics (less than $10,000), and from other companies that are unrelated to this study. This information is on file at the journal.

  6. ††

    Dr. Gravallese has received consulting fees from Abbott (less than $10,000). The BRASS registry was supported by Millennium Pharmaceuticals, Riley Genomics, and Biogen Idec.

*Division of Rheumatology, Brigham and Women's Hospital, 75 Francis Street, PBB-B3, Boston, MA 02115

Publication History

  1. Issue published online: 28 MAY 2009
  2. Article first published online: 28 MAY 2009
  3. Manuscript Accepted: 25 FEB 2009
  4. Manuscript Received: 9 JUN 2008

Funded by

  • NIH. Grant Numbers: AG-027066, AR-047782, AR-055989, K24-DK-02759, AR-047665
  • CDC
  • Worcester Foundation

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (81K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Nicola J. Gullick, David L. Scott, Co-morbidities in established rheumatoid arthritis, Best Practice & Research Clinical Rheumatology, 2011, 25, 4, 469

    CrossRef

  2. 2
    Julie C Baker-LePain, Mary C Nakamura, Nancy E Lane, Effects of inflammation on bone: an update, Current Opinion in Rheumatology, 2011, 23, 4, 389

    CrossRef

  3. 3
    Piet Geusens, Willem F Lems, Osteoimmunology and osteoporosis, Arthritis Research & Therapy, 2011, 13, 5, 242

    CrossRef

  4. 4
    Jie Zhang, David T. Redden, Gerald McGwin, Leigh F. Callahan, Edwin A. Smith, Graciela S. Alarcón, Larry W. Moreland, Désirée M. van der Heijde, Elizabeth E. Brown, Donna K. Arnett, Ted R. Mikuls, S. Louis Bridges, Generalized bone loss as a predictor of three-year radiographic damage in African American patients with recent-onset rheumatoid arthritis, Arthritis & Rheumatism, 2010, 62, 8
    Direct Link:
  5. 5
    Gert Hein, Thorsten Eidner, Peter Oelzner, Michael Rose, Alexander Wilke, Gunter Wolf, Sybille Franke, Influence of Rituximab on markers of bone remodeling in patients with rheumatoid arthritis: a prospective open-label pilot study, Rheumatology International, 2010, 31, 2, 269

    CrossRef

  6. 6
    Yong-Chan Ha, Meta-analysis on the Risk Factors for Fracture in Patients with Rheumatoid Arthritis, The Journal of the Korean Rheumatism Association, 2010, 17, 2, 105

    CrossRef

  7. 7
    A. El Maghraoui, A. Rezqi, A. Mounach, L. Achemlal, A. Bezza, I. Ghozlani, Prevalence and risk factors of vertebral fractures in women with rheumatoid arthritis using vertebral fracture assessment, Rheumatology, 2010, 49, 7, 1303

    CrossRef

  8. 8
    C. K. Iannaccone, Y. C. Lee, J. Cui, M. L. Frits, R. J. Glass, R. M. Plenge, D. H. Solomon, M. E. Weinblatt, N. A. Shadick, Using genetic and clinical data to understand response to disease-modifying anti-rheumatic drug therapy: data from the Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study, Rheumatology, 2010, 50, 1, 40

    CrossRef

  9. 9
    S. P. Desai, E. M. Gravallese, N. A. Shadick, R. Glass, J. Cui, M. Frits, L. B. Chibnik, N. Maher, M. E. Weinblatt, D. H. Solomon, Hand bone mineral density is associated with both total hip and lumbar spine bone mineral density in post-menopausal women with RA, Rheumatology, 2009, 49, 3, 513

    CrossRef

View Full Article (HTML) Get PDF (81K)